AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...

The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...